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INTRODUCTION
Trigger finger (TF) is one of the most common conditions treated by hand surgeons with a
lifetime risk up to 10% in patients with diabetes. If conservative management fails, surgical
treatment is undertaken, with or without sedation and a tourniquet, via a small incision to
release the A1 pulley. A number of local anesthetics are readily available including Lidocaine,
Ropivacaine and Marcaine as well as encapsulated formulations thereof such as Exparel.
Since it’s approval in 2011, there have been numerous reports of successfully achieving prolonged pain relief with locally injected Exparel after various procedures, but to the best of
our knowledge there have been no reports of its use in ambulatory hand surgery. In this
study we prospectively evaluated the efficacy of Lidocaine, Marcaine, or bupivacaine with
post-operative Exparel in controlling pain, opioid usage, and adverse reactions following TF
surgery.

MATERIALS AND METHODS
After obtaining institutional review board (IRB) approval, all consecutive patients scheduled
to undergo single digit TF surgery were invited to participate. All procedures were performed
under local anesthesia without sedation by one of seven fellowship-trained hand surgeons.
The technique for injection was that of a single volar injection at the level of the A1 pulley
with a volume of 5-10 ml of local anesthetic delivered subcutaneously and superficial to the
flexor tendon sheath. The injectate consisted of either a) 1% Lidocaine, b) 0.5% Marcaine, or
0.5% bupivacaine with post-operative injection of 5cc of Exparel into the closed surgical site.
Patients were instructed to record their medication use, their pain levels using a Visual
Analog Scale (VAS) scoring system and any adverse reactions experienced. An analysis of
variance was used to detect significant differences between groups.

RESULTS
DEMOGRAPHICS
Patients were enrolled over a 6 month period in 2014. The study consisted of a total of 163
patients (85 women and 78 men), with only 9 patients lost to follow up for an overall attrition
rate of 5.5%. After excluding patients lost to follow up, the Marcaine group included 50 patients with average age of 61.3, the Lidocaine group included 53 patients with average age of
65, and the Exparel group included 51 patients with average age of 64.

FIGURES 1 - 5
PAIN-FREE PATIENTS WITHOUT OPIOIDS
An analysis of patients that were deemed pain-free
(VAS score ≤2) while also not using any opioid medication revealed that on POD 0, 50% of patients that
received Exparel were pain-free without requiring
opioids, which was statistically higher than Lidocaine
at 16% (p=0.002) and Marcaine at 21% (p=0.017). This
trend continued on POD 1 with Exparel at 47%
(p=0.474), Marcaine at 40% and Lidocaine at 32%
(p=0.118). By POD 2-3 the patients in this category
converged with no statistical differences.

VISUAL ANALOG SCALE (VAS) SCORES
Patients were contacted on POD 3 and asked
about their pain levels over POD 0-3. On POD 0
patients in the Lidocaine group reported the
most pain. On POD 1 this difference was maintained with the lidocaine group at 3.73 as compared to the Marcaine and Exparel groups at 2.90
(p=0.116) and 2.33 (p=0.003), respectively.Only
the Exparel group maintained significance on
POD 1. In contrast, on POD 2 and POD 3 the differences were more subtle and did not reach statistical significance.
OPIOID CONSUMPTION: PERCENT OF PATIENT USAGE
On POD 0, 58% (p=0.01) and 59% (p=0.004) of
patients that received Marcaine and Lidocaine,
respectively, used opioids for pain control as
compared to 27% of patients in the Exparel
group.
By POD 1, Exparel patients maintained the
lowest opioid consumption at 33.3%, where 44%
(p=0.271) and 45% (p=0.213) of the Lidocaine
and Marcaine patients used opioids.
At POD 2 the percentage of patients using opioids continued to decrease in all groups and
converged to about 15% by POD 3.
OPIOID CONSUMPTION: NUMBER OF TABLETS
A similar trend is seen when the average total
number of opioid pills consumed by these groups is
analyzed. The only statistically different pill consumption was observed on POD 0 where opioid
users in the lidocaine group consumed an average of
1.62 pills as compared to 1.08 (p=0.214) and 0.70
(p=0.013) pills in the Marcaine and Exparel group,
respectively. Total pill consumption on POD 1-3 was
similar in all groups.

ADVERSE EFFECTS
The percentage of patients reporting any adverse reactions at any time in the first 3 days after surgery was significantly lower in the Exparel group (3%) as compared
to the Marcaine 13% ( p = 0.017) and Lidocaine 10%
(p=0.133) group. The most common reactions reported
included dry mouth, nausea, lack of energy and itching
whereas the least common reactions were dizziness,
coughing and a sensation of bloating.

DISCUSSION

DISCUSSION
To the best of our knowledge this is the first report on the comparative efficacy of local anesthetics in ambulatory hand surgery specifically comparing Lidocaine, Marcaine, and Exparel.
Our results suggest that patients treated with Marcaine attain better pain control than those
treated with Lidocaine on POD 0-1, but only patients that receive Exparel maintain the lowest
pain levels through POD 0-3. More importantly, this is achieved while using little-to-no opioid
medications and with less adverse reactions than with Lidocaine or Marcaine alone. In agreement with what has been reported in other series, Exparel generally appears to make most of
the difference in pain perception in the first 1-2 days after surgery. Overall, pain following trigger finger release surgery performed wide-awake and without a tourniquet is low. However,
longer pain relief, decreased opioid consumption, and a better adverse reaction profile is a
goal that physicians and patients strive to achieve. More studies are needed to validate both
the efficacy and cost of Exparel versus other local anesthetic agents in patients undergoing
more extensive and painful hand and orthopaedic surgical procedures.

